Proteasome– tag –
-
FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%
Dana-Farber Cancer Institute USA Overview The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harborin... -
Tango Therapeutics Unveils TNG961, First Selective Oral HBS1L Molecular Glue Degrader for FOCAD-Deleted Cancers, a New Precision Oncology Strategy
AACR Journals (Cancer Discovery) USA Overview Tango Therapeutics announced the development of TNG961, the first selective oral HBS1L molecular glue degrader targeting FOCAD-deleted cancers. TNG961 induces translational arrest by disrupti... -
First Oral ER PROTAC Vepdegestrant Gains FDA Approval, Ushering New Era in Targeted Protein Degradation
MDPI Switzerland Overview The field of Targeted Protein Degradation (TPD) marks a significant milestone with the FDA approval of vepdegestrant (VEPPANU, ARV-471), the first oral estrogen receptor (ER) targeted PROTAC, co-developed by Arv... -
Targeted Protein Degradation (TPD) Enters Decisive Clinical Phase, Evolving Beyond PROTACs to Multifunctional Therapeutics
European Biotechnology Magazine Europe Overview Targeted protein degradation (TPD) is poised for a major clinical breakthrough, with 2026 marking a decisive phase as a diverse pipeline of next-generation degraders, including molecular gl... -
GZL626, a Novel Molecular Glue Degrader for Androgen Receptor (AR/AR-V7), Overcomes Resistance in Advanced Prostate Cancer
bioRxiv Unknown Overview A preprint on bioRxiv describes the identification of GZL626, a novel small-molecule molecular glue degrader that induces proteasome-dependent degradation of both full-length androgen receptor (AR) and its splice... -
Pfizer and Arvinas’ Veppanu (vepdegestrant) Gains FDA Approval, Revolutionizing ESR1-Mutated Advanced Breast Cancer as First PROTAC
DCAT Value Chain Insights USA Overview In 2026, Pfizer and Arvinas' Veppanu (vepdegestrant) received FDA approval for advanced breast cancer with ESR1 mutations, becoming the first FDA-approved PROTAC. This drug offers a groundbreaking o... -
Exponential Progression in Targeted Protein Degradation (TPD) Drug Discovery: New Modality Accelerates Drug Development
MarinBio USA Overview MarinBio published an article highlighting the exponential progression in Targeted Protein Degradation (TPD) drug discovery, establishing it as a primary, accelerating modality in novel drug development. TPD technol... -
Nurix Therapeutics’ Bexobrutideg Shows 83% ORR and 22.1 Months PFS in Relapsed/Refractory CLL/SLL Phase 1 Study
Nurix Therapeutics USA Overview Nurix Therapeutics reported updated clinical data from its NX-5948-301 Phase 1a/1b study, showing durable responses and a favorable tolerability profile for bexobrutideg in relapsed/refractory CLL/SLL pati... -
Exponential Progression of Targeted Protein Degradation: First FDA-Approved PROTAC and Molecular Glues Unlock “Undruggable” Targets
MarinBio (Appears to be a scientific review/journal, affiliated with MarinBio, hence using their domain) USA Overview The field of targeted protein degradation (TPD) is rapidly evolving, enabling the degradation of previously "undruggabl... -
Arvinas/Pfizer’s PROTAC Drug Veppanu Receives Historic FDA Approval for ESR1-Mutant Advanced Breast Cancer, Demonstrating 43% PFS Risk Reduction
Cancer Discovery - AACR Journals USA Overview Arvinas and Pfizer's oral PROTAC drug, Veppanu, has received FDA approval for advanced breast cancer with ESR1 mutations, marking the first clinical validation of targeted protein degradation...
